Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab'

被引：8
|
作者：
Bibeau, F. [1 ]
Gil, H. [1 ]
Castan, F. [2 ]
Boissiere-Michot, F. [1 ]
机构：
[1] Inst Reg Canc Montpellier, Dept Pathol, F-34298 Montpellier 5, France
[2] Inst Reg Canc Montpellier, Biostat Unit, F-34298 Montpellier 5, France
来源：
BRITISH JOURNAL OF CANCER | 2013年 / 109卷 / 12期
关键词：
CHEMOTHERAPY;
D O I：
10.1038/bjc.2013.651
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3127 / 3129
页数：4
相关论文
共 50 条
  • [1] Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab’
    F Bibeau
    H Gil
    F Castan
    F Boissière-Michot
    [J]. British Journal of Cancer, 2013, 109 : 3127 - 3129
  • [2] Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'
    Schirripa, M.
    Loupakis, F.
    Pollina, L.
    Cremolini, C.
    Pasquini, G.
    Falcone, A.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 109 (12) : 3129 - 3130
  • [3] Reply: Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab’
    M Schirripa
    F Loupakis
    L Pollina
    C Cremolini
    G Pasquini
    A Falcone
    [J]. British Journal of Cancer, 2013, 109 : 3129 - 3130
  • [4] Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
    Loupakis, F.
    Schirripa, M.
    Caparello, C.
    Funel, N.
    Pollina, L.
    Vasile, E.
    Cremolini, C.
    Salvatore, L.
    Morvillo, M.
    Antoniotti, C.
    Marmorino, F.
    Masi, G.
    Falcone, A.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 108 (12) : 2549 - 2556
  • [5] Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
    F Loupakis
    M Schirripa
    C Caparello
    N Funel
    L Pollina
    E Vasile
    C Cremolini
    L Salvatore
    M Morvillo
    C Antoniotti
    F Marmorino
    G Masi
    A Falcone
    [J]. British Journal of Cancer, 2013, 108 : 2549 - 2556
  • [6] Histopathologic response to FOLFOXIRI plus bevacizumab of liver metastases from colorectal cancer.
    Schirripa, M.
    Loupakis, F.
    Caparello, C.
    Funel, N.
    Pollina, L.
    Vasile, E.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Fornaro, L.
    Campani, D.
    Falcone, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] HISTOPATHOLOGICAL RESPONSE TO FOLFOXIRI PLUS BEVACIZUMAB OF LIVER METASTASES FROM COLORECTAL CANCER
    Caparello, Chiara
    Loupakis, Fotios
    Schirripa, Marta
    Funel, Niccola
    Pollina, Luca
    Vasile, Enrico
    Cremolini, Chiara
    Salvatore, Lisa
    Masi, Gianluca
    Fornaro, Lorenzo
    Campani, Daniela
    Falcone, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : v95 - v95
  • [8] FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
    Antoniotti, Carlotta
    Vetere, Guglielmo
    Cremolini, Chiara
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (18)
  • [9] FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?
    Modest, D. P.
    Neumann, U. P.
    Pratschke, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 73 : 71 - 73
  • [10] Impact of FOLFOXIRI plus bevacizumab on resectability and survival in patients with initially unresectable liver metastases from colorectal cancer.
    Shimada, M.
    Nishioka, M.
    Hanaoka, J.
    Mori, H.
    Ikemoto, T.
    Imura, S.
    Morine, Y.
    Utsunomiya, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345